SLC2A1 and esophageal squamous cell carcinoma: Taken altogether, our current data presented herein suggest that SLC2A1-AS1/miR-378a-3p/Glut1 regulatory axis plays an essential role in ESCC development and progression, and thus targeting the signal axis may be a novel therapeutic target for ESCC patients.